By: Joy Lin
Moderna has entered a partnership with Generation Bio to combine their technologies and develop lipid nanoparticles using Generation Bio’s stealth cell-targeted lipid nanoparticle (ctLNP) delivery system. The collaboration is expected to advance the companies' respective pipelines of non-viral genetic medicines.